Cell death mechanisms associated with G2 radiosensitivity in patients with prostate cancer and benign prostatic hyperplasia

被引:15
|
作者
Howe, O
O'Malley, K
Lavin, M
Gardner, RA
Seymour, C
Lyng, F
Mulvin, D
Quinlan, DM
Mothersill, C
机构
[1] Dublin Inst Technol, Focus Inst, Radiat & Environm Sci Ctr, Dublin 8, Ireland
[2] St Vincents Hosp, Dept Urol, Dublin 4, Ireland
[3] Univ Queensland, Ctr Clin Sch, Queensland Inst Med Res, Brisbane, Qld 4029, Australia
[4] St Lukes Hosp, Radiat Sci Ctr, Dublin 8, Ireland
关键词
D O I
10.1667/RR3454.1
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Cells respond to genotoxic insults such as ionizing radiation by halting in the G(2) phase of the cell cycle. Delayed cell death (mitotic death) can occur when the cell is released from G(2), and specific spindle defects form endopolyploid cells (endoreduplication/tetraploidy). Enhanced G(2) chromosomal radiosensitivity has been observed in many cancers and genomic instability syndromes, and it is manifested by radiation-induced chromatid aberrations observed in lymphocytes of patients. Here we compare the G(2) chromosomal radiosensitivity in prostate patients with benign prostatic hyperplasia (BPH) or prostate cancer with disease-free controls. We also investigated whether there is a correlation between G(2) chromosomal radiosensitivity and aneuploidy (tetraploidy and endoreduplication), which are indicative of mitotic cell death. The G(2) assay was carried out on all human blood samples. Metaphase analysis was conducted on the harvested chromosomes by counting the number of aberrations and the mitotic errors (endoreduplication/tetraploidy) separately per 100 metaphases. A total of 1/14 of the controls were radiosensitive in G(2) compared to 6/15 of the BPH patients and 15/17 of the prostate cancer patients. Radiation-induced mitotic inhibition was assessed to determine the efficacy of G(2) checkpoint control in the prostate patients. There was no significant correlation of G(2) radiosensitivity scores and mitotic inhibition in BPH patients (P = 0.057), in contrast to prostate cancer patients, who showed a small but significant positive correlation (P = 0.029). Furthermore, there was no significant correlation between G(2) radiosensitivity scores of BPH patients and endoreduplication/ tetraploidy (P = 0.136), which contrasted with an extremely significant correlation observed in prostate cancer patients (P < 0.0001). In conclusion, cells from prostate cancer patients show increased sensitivity to the induction of G(2) aberrations from ionizing radiation exposure but paradoxically show reduced mitotic indices and aneuploidy as a function of aberration frequency.
引用
收藏
页码:627 / 634
页数:8
相关论文
共 50 条
  • [31] Oxidative Stress and Body Composition in Prostate Cancer and Benign Prostatic Hyperplasia Patients
    Cimino, Sebastiano
    Favilla, Vincenzo
    Russo, Giorgio Ivan
    Galvano, Fabio
    Li Volti, Giovanni
    Barbagallo, Ignazio
    Giofre, Salvatore Vincenzo
    D'Orazio, Nicolantonio
    Di Rosa, Alessandro
    Madonia, Massimo
    Morgia, Giuseppe
    ANTICANCER RESEARCH, 2014, 34 (09) : 5051 - 5056
  • [32] Benign prostate, prostatic hyperplasia, and prostatic carcinoma in female patients.
    Sesterhenn, IA
    Davis, CJ
    Mostofi, FK
    MODERN PATHOLOGY, 1998, 11 (01) : 95A - 95A
  • [33] Impact of Benign Prostatic Hyperplasia and/or Prostatitis on the Risk of Prostate Cancer in Korean Patients
    Kim, Sung Han
    Kwon, Whi An
    Joung, Jae Young
    WORLD JOURNAL OF MENS HEALTH, 2021, 39 (02): : 358 - 365
  • [34] Cytokeratin 8/18 levels in patients with prostate cancer and benign prostatic hyperplasia
    Wolff, JM
    Borchers, H
    Brehmer, B
    Brauers, A
    Jakse, G
    UROLOGIA INTERNATIONALIS, 1998, 60 (03) : 152 - 155
  • [35] Serum interleukin-11 in patients with benign prostatic hyperplasia and prostate cancer
    Furuya Y.
    Nishio R.
    Junicho A.
    Nagakawa O.
    Fuse H.
    International Urology and Nephrology, 2005, 37 (1) : 69 - 71
  • [36] Identification of Programmed Cell Death (PCD) associated genes in diagnosing benign prostatic hyperplasia and prostate cancer by integrated bioinformatics analysis and machine learning
    Jie, C.
    Bo, C.
    Dehong, C.
    EUROPEAN UROLOGY, 2024, 85 : S2101 - S2101
  • [37] Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer
    Mohamed S. Fawzy
    Randa H. Mohamed
    Abdel-Rahman R. Elfayoumi
    Medical Oncology, 2015, 32
  • [38] Prostate stem cell antigen (PSCA) mRNA expression in peripheral blood in patients with benign prostatic hyperplasia and/or prostate cancer
    Fawzy, Mohamed S.
    Mohamed, Randa H.
    Elfayoumi, Abdel-Rahman R.
    MEDICAL ONCOLOGY, 2015, 32 (03)
  • [39] Tissue Proteome Signatures Associated with Five Grades of Prostate Cancer and Benign Prostatic Hyperplasia
    Kawahara, Rebeca
    Recuero, Saulo
    Nogueira, Fabio C. S.
    Domont, Gilberto B.
    Leite, Katia R. M.
    Srougi, Miguel
    Thaysen-Andersen, Morten
    Palmisano, Giuseppe
    PROTEOMICS, 2019, 19 (21-22)
  • [40] Trombospondin 2 Expression Profile in Prostate Cancer and Benign Prostatic Hyperplasia Tissues
    da Rocha Matos, A.
    Coutinho-Camillo, C. M.
    Damascena, A. S.
    Silva, E. A.
    Brentani, H. P.
    Fonseca, F. P.
    Soares, F. A.
    Gimba, E. R. P.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S35 - S36